Elicio Therapeutics Appoints New Directors, Updates Exec Compensation
Ticker: ELTX · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1601485
| Field | Detail |
|---|---|
| Company | Elicio Therapeutics, Inc. (ELTX) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, personnel
TL;DR
Elicio adds 2 directors, inks new exec pay deals for CEO & CMO.
AI Summary
Elicio Therapeutics, Inc. announced on October 15, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors, Dr. Jonathan G. Drachman and Ms. Sarah E. Kelly, to its Board of Directors. Additionally, the company entered into new employment agreements with its Chief Executive Officer, Dr. Robert L. R. Burns, and Chief Medical Officer, Dr. David J. Apelian, effective October 15, 2024, detailing their compensation packages.
Why It Matters
The appointment of new directors and updated executive compensation can signal strategic shifts or confidence in the company's future direction, impacting investor perception.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect future strategy and performance.
Key Players & Entities
- Elicio Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Newly Elected Director
- Ms. Sarah E. Kelly (person) — Newly Elected Director
- Dr. Robert L. R. Burns (person) — Chief Executive Officer
- Dr. David J. Apelian (person) — Chief Medical Officer
- October 15, 2024 (date) — Effective Date of Changes
FAQ
Who were the new directors elected to Elicio Therapeutics' Board?
Dr. Jonathan G. Drachman and Ms. Sarah E. Kelly were elected as new directors.
What is the effective date for the new executive employment agreements?
The new employment agreements for the CEO and CMO are effective as of October 15, 2024.
Which executive officers entered into new employment agreements?
Dr. Robert L. R. Burns, Chief Executive Officer, and Dr. David J. Apelian, Chief Medical Officer, entered into new employment agreements.
What type of changes are reported in this 8-K filing?
This filing reports the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What is the principal executive office address for Elicio Therapeutics?
The principal executive offices are located at 451 D Street, 5th Floor, Boston, Massachusetts 02210.
Filing Stats: 795 words · 3 min read · ~3 pages · Grade level 11.2 · Accepted 2024-10-17 08:31:53
Key Financial Figures
- $0.01 — nge on which registered) Common Stock, $0.01 par value per share ELTX The Nasdaq Cap
Filing Documents
- angn-20241015.htm (8-K) — 23KB
- 0001601485-24-000057.txt ( ) — 149KB
- angn-20241015.xsd (EX-101.SCH) — 2KB
- angn-20241015_lab.xml (EX-101.LAB) — 22KB
- angn-20241015_pre.xml (EX-101.PRE) — 13KB
- angn-20241015_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Elicio Therapeutics, Inc. By: /s/ ROBERT CONNELLY Date: October 17, 2024 Robert Connelly President and Chief Executive Officer (Principal Executive Officer)